SNGX

Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more

Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

by
Zacks Small Cap Research – SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… – Go Health Pro

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Marburg Virus Outbreak Puts Focus on Soligenix Vaccine Development Soligenix, Inc. (NASDAQ:SNGX) is developing vaccines targeting multiple filoviruses, including MarVax, a heat stable vaccine for protection against Marburg virus. Recent events highlight the importance of the company’s vaccine development program. On October … Read more

x